| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 15 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE O... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer – |
| 30 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure +1 more
Strengthens Leadership with Veteran Executives with Decades of Industry Experience |
| 26 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more
On June 25, 2026, ALX Oncology Holdings Inc., a Delaware corporation (the “Company”), entered into a loan and security agreement (the “Loan Agreement”) among HSBC Ventures USA Inc., as lender, ALX Oncology Inc., a Delaware corporation (“... |
| 11 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
ALX Oncology Holdings Inc. (the “Company”) held its Annual Meeting of stockholders (the “Annual Meeting”) on June 10, 2026. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below. |
| 08 May 2026 |
8-K: Results of Operations and Financial Condition
- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination - |
| 13 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution |
| 27 Feb 2026 |
8-K: Results of Operations and Financial Condition
- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets... |
| 30 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Introductory. ALX Oncology Holdings Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 76,979,112 shares (the “Shares”) of its... |
| 30 Jan 2026 |
8-K: Other Events
- Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – |
| 21 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Purpose of the Plan. The purpose of this Plan is to attract and retain the best available personnel by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary of the Company. |
| 07 Nov 2025 |
8-K: Results of Operations and Financial Condition
– ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients with high CD47 expression |
| 12 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
– Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company’s Board of Directors and will step down from the Board to join ALX as Interim Chi... |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more
– Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be presented at a medical conference in Q4 2025 |
| 12 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
ALX Oncology Holdings Inc. (the “Company”) held its Annual Meeting of stockholders (the “Annual Meeting”) on June 11, 2025. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below. |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
– Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies in mid-2025 |
| 25 Apr 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On April 23, 2025, ALX Oncology Holdings Inc. (the “Company”) received a written notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has not been in complianc... |
| 06 Mar 2025 |
8-K: Results of Operations and Financial Condition
– Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral presentation at 2025 ASCO GI |
| 05 Mar 2025 |
8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation
On February 28, 2025, the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) approved a reduction in the Company’s workforce by approximately 30% of the Company’s employees in connection with the Company pipel... |
Loading...